Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients

ConclusionsImmune-related response evaluations using irRECIST1.1 in advanced NSCLC patients treated with nivolumab resulted in the identical response rate and longer TTP compared to RECIST1.1. No pseudoprogression cases were observed during the study. Adrenal lesions and lymph nodes were more responsive and liver lesions were less responsive to nivolumab.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research